Norda ASA

Equities

NORD

NO0010285190

Biotechnology & Medical Research

End-of-day quote Norwegian OTC Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
41 ^NOK	-.--%		-.--%	-.--%

2023	Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2022	Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021	CI

Norda ASA Obtains NOK 35 Million Line of Credit from a Norwegian Bank

October 12, 2012 at 03:33 pm IST

Norda ASA has obtained a line of credit from a Norwegian bank of NOK 35 million. The funds will strengthen the company's capital base, as well as optimise cash management. The line of credit can be withdrawn by the bank with one month notice.

Latest news about Norda ASA

Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022	01/11	CI
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
Norda Asa Reports Earnings Results for the Full Year Ended December 31, 2020	21/21/21	CI
Norda ASA Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2013	22/13/22	CI
Norda ASA Reports Unaudited Net Debt Results as of December 31, 2012	09/13/09	CI
Norda ASA Appoints Scient Frode Westvold as CEO	09/13/09	CI
Norda ASA Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2012	28/13/28	CI
Norda ASA Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012	31/12/31	CI
Norda ASA Obtains NOK 35 Million Line of Credit from a Norwegian Bank	12/12/12	CI
Norda ASA Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	29/12/29	CI
NorDiag ASA will Change its Name to Norda ASA	04/12/04	CI
NorDiag ASA's Equity Buyback has expired	21/12/21	CI
A family acquired 20.8% stake in NorDiag ASA (OB:NORD).	01/12/01	CI
NorDiag ASA Announces Management Changes	30/12/30	CI
NorDiag ASA Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012	24/12/24	CI
NorDiag ASA Auditor Raises 'Going Concern' Doubt	27/12/27	CI
NorDiag ASA Reports Earnings Results for the Year Ended December 31, 2011	27/12/27	CI
Tranche Update on NorDiag ASA's Equity Buyback Plan announced on May 9, 2011.	27/12/27	CI
NorDiag ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011	16/12/16	CI
NorDiag ASA and Xiril AG to Launch the Bullet Pro an Advanced High Throughput Sample Preparation Instrument	15/12/15	CI

Chart Norda ASA

Duration

Period

More charts

Company Profile

Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Companyâs products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
NORDA ASA	-.--%	19.12M
EXACT SCIENCES CORPORATION	-42.89%	7.8B
GUARDANT HEALTH, INC.	+6.77%	3.53B
BGI GENOMICS CO., LTD.	-27.06%	1.84B
VERACYTE, INC.	-21.23%	1.66B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+9.31%	951M
CAREDX, INC	+29.42%	811M
SEEGENE, INC.	-12.66%	670M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-26.12%	533M
CURIOX BIOSYSTEMS CO., LTD	+1.19%	297M

Bio Diagnostics & Testing